FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to fused proteins based on TGF-beta receptor; it can be used in medicine for the treatment of PD-L1-mediated tumor. Bifunctional fused protein is proposed, containing a targeting part – an antibody against PD-L1 and extracellular domain TGF-beta RII.
EFFECT: invention provides for obtaining fused proteins that are specific relatively to binding to human TGF-beta1 and PD-L1, block binding to PD-1 and inhibit TGF-bets-induced pSMAD3 activity, as well as show a higher expression level and a stable structure compared to fused protein of the similar structure based on uncut ECD TGF-beta RII.
19 cl, 8 dwg, 10 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
